share_log

Cybin | 6-K: Report of foreign private issuer (related to financial reporting)

Cybin | 6-K: Report of foreign private issuer (related to financial reporting)

Cybin | 6-K：外國發行人報告（業績相關）
美股sec公告 ·  03/21 13:56
Moomoo AI 已提取核心訊息
Cybin Inc. (Cybin), a biopharmaceutical company, has announced the completion of a private placement offering of common shares, raising gross proceeds of up to $150 million. The offering was conducted on a 'commercially reasonable efforts' basis by Bloom Burton Securities Inc. (Lead Agent) and Haywood Securities Inc. (collectively, the 'Agents'). The shares were priced at $0.43 each, with the event dated March 19, 2024. The offering was made to purchasers in Canada, the United States, and offshore jurisdictions, exempt from registration requirements under U.S. securities laws. The Agents were entitled to an offering fee of 6.0% of the aggregate gross proceeds, reduced to 3.0% for president's list purchasers introduced by Cybin. The offering aimed to issue and sell common shares without underwriter liability, with the Agents appointing other dealers to assist in the offering. The Agents were responsible for their remuneration, payable from their offering fee. The offering's completion was subject to customary closing conditions, including regulatory approvals and the execution of subscription agreements with purchasers.
Cybin Inc. (Cybin), a biopharmaceutical company, has announced the completion of a private placement offering of common shares, raising gross proceeds of up to $150 million. The offering was conducted on a 'commercially reasonable efforts' basis by Bloom Burton Securities Inc. (Lead Agent) and Haywood Securities Inc. (collectively, the 'Agents'). The shares were priced at $0.43 each, with the event dated March 19, 2024. The offering was made to purchasers in Canada, the United States, and offshore jurisdictions, exempt from registration requirements under U.S. securities laws. The Agents were entitled to an offering fee of 6.0% of the aggregate gross proceeds, reduced to 3.0% for president's list purchasers introduced by Cybin. The offering aimed to issue and sell common shares without underwriter liability, with the Agents appointing other dealers to assist in the offering. The Agents were responsible for their remuneration, payable from their offering fee. The offering's completion was subject to customary closing conditions, including regulatory approvals and the execution of subscription agreements with purchasers.
生物製藥公司Cybin Inc.（Cybin）宣佈完成普通股的私募發行，總收益高達1.5億美元。此次發行是由布魯姆·伯頓證券公司（牽頭代理人）和海伍德證券公司（統稱爲 “代理人”）在 “商業上合理的努力” 的基礎上進行的。這些股票的定價爲每股0.43美元，活動日期爲2024年3月19日。此次發行是針對加拿大、美國和離岸司法管轄區的購買者進行的，不受美國證券法規定的註冊要求的約束。代理商有權獲得總收益的6.0％的發行費，對於Cybin推出的總裁名單購買者，則降至3.0％。此次發行旨在發行和出售普通股，無需承銷商承擔責任，代理商將指定其他交易商協助發行。代理商負責支付報酬，從報價中支付。此次發行的完成取決於慣例成交條件，包括監管部門的批准和與買方簽訂的訂閱協議的執行。
生物製藥公司Cybin Inc.（Cybin）宣佈完成普通股的私募發行，總收益高達1.5億美元。此次發行是由布魯姆·伯頓證券公司（牽頭代理人）和海伍德證券公司（統稱爲 “代理人”）在 “商業上合理的努力” 的基礎上進行的。這些股票的定價爲每股0.43美元，活動日期爲2024年3月19日。此次發行是針對加拿大、美國和離岸司法管轄區的購買者進行的，不受美國證券法規定的註冊要求的約束。代理商有權獲得總收益的6.0％的發行費，對於Cybin推出的總裁名單購買者，則降至3.0％。此次發行旨在發行和出售普通股，無需承銷商承擔責任，代理商將指定其他交易商協助發行。代理商負責支付報酬，從報價中支付。此次發行的完成取決於慣例成交條件，包括監管部門的批准和與買方簽訂的訂閱協議的執行。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息